NOT KNOWN DETAILS ABOUT LINSITINIB

The LIDS trial fulfilled its Most important endpoint with statistical significance for that 150mg BID dose. Linsitinib in this trial validated the safety profile observed from the prior oncology research and importantly demonstrated a favorable security profile on important adverse activities (AEs) of fascination for that IGF-1R concentrate on such